Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Acorda Therapeutics

    • Home
    • Acorda Therapeutics
Company Deals

Acorda Therapeutics Strikes Deal with Hangzhou Chance for Inbrija Distribution in China

Fineline Cube May 9, 2023

US-based Acorda Therapeutics Inc., (Nasdaq: ACOR) has announced a distribution and supply agreement with Hangzhou...

Company Deals

Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris

Fineline Cube Sep 2, 2022

US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...

Recent updates

  • MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes
  • Pfizer Reports Mixed Phase 3 Results for Sigvotatug Vedotin in Non-Small Cell Lung Cancer
  • Anhui Province Launches National Alliance for Monoclonal Antibody Biologics Volume-Based Procurement
  • Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager
  • CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes

Company Drug

Pfizer Reports Mixed Phase 3 Results for Sigvotatug Vedotin in Non-Small Cell Lung Cancer

Policy / Regulatory

Anhui Province Launches National Alliance for Monoclonal Antibody Biologics Volume-Based Procurement

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.